46 Participants Needed

Lidocaine Infusion for Pancreatic Cancer

AB
GE
Overseen ByGina E. Votta-Velis, MD PhD
Age: 18+
Sex: Any
Trial Phase: Phase < 1
Sponsor: University of Illinois at Chicago
Approved in 5 JurisdictionsThis treatment is already approved in other countries

Trial Summary

Will I have to stop taking my current medications?

The trial does not specify if you need to stop taking your current medications, but you cannot participate if you are currently taking certain heart medications like quinidine, flecainide, disopyramide, or procainamide, or if you have been treated with amiodarone in the past.

What data supports the effectiveness of the drug lidocaine for pancreatic cancer?

A study found that intravenous lidocaine during pancreatic cancer surgery is linked to reduced opioid use and may improve long-term survival, suggesting potential benefits for patients undergoing surgery.12345

Is lidocaine safe for use in humans?

Lidocaine is generally safe for use in humans, but there are risks of overdose, especially in children, when used in high doses or frequently. It has been used safely in various forms for pain relief, but caution is needed to avoid toxic reactions, particularly with viscous lidocaine.678910

How is the drug lidocaine used in treating pancreatic cancer different from other treatments?

Lidocaine infusion for pancreatic cancer is unique because it is administered intravenously during surgery and may improve long-term survival by reducing inflammation and possibly having anti-tumor effects, unlike standard treatments that primarily focus on chemotherapy or radiation.16111213

What is the purpose of this trial?

This study elucidates the effects of the intravenous (IV) lidocaine infusion on the biology of pancreatic circulating tumor cells (CTCs) isolated from patients undergoing robotic pancreatectomy for all types of pancreatic cancer.A prospective randomized controlled double blinded trial design will be used for the proposed study.

Research Team

GE

Gina E. Votta-Velis, MD PhD

Principal Investigator

Associate Professor

Eligibility Criteria

This trial is for patients with pancreatic cancer that was initially thought to be removable but found to have spread at surgery. They may have had previous treatments like chemo. Participants must understand and sign a consent form, and their cancer should be measurable by certain medical criteria.

Inclusion Criteria

My cancer was thought to be removable but was found to have spread during surgery.
I have read, understood, and signed the approved consent form.
I have at least one tumor that can be measured.
See 2 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive either a 24-hour lidocaine infusion or a saline infusion during the perioperative period

24 hours
In-hospital during surgery

Follow-up

Participants are monitored for safety and effectiveness after treatment, with blood samples collected perioperatively

1-2 weeks

Treatment Details

Interventions

  • Lidocaine Hydrochloride
Trial Overview The study is testing the effects of IV lidocaine (a local anesthetic) on circulating tumor cells in patients undergoing robotic surgery for pancreatic cancer. It's a controlled experiment where neither doctors nor patients know who gets lidocaine or a saline placebo.
Participant Groups
2Treatment groups
Experimental Treatment
Placebo Group
Group I: Lidocaine HydrochlorideExperimental Treatment1 Intervention
The IV bolus and infusions of lidocaine to those patients assigned to the lidocaine group will be started in the operating room and will continue until 24 h later. The group receiving the lidocaine infusion will first be administered a 1.0 - 1.5 mg/kg loading infusion over 5 minutes followed by a 1.0 - 1.5 mg/kg/h infusion for 24 h
Group II: Saline Solution for InjectionPlacebo Group1 Intervention
The group receiving the saline infusion will be administered an equivalent volume of saline infused over 5 min followed by a saline infusion at the same flow rate as that used in the lidocaine group for 24 h (1.0 - 1.5 mg/kg/hr)

Lidocaine Hydrochloride is already approved in European Union, United States, Canada, Japan for the following indications:

πŸ‡ͺπŸ‡Ί
Approved in European Union as Xylocaine for:
  • Local anesthesia
  • Regional anesthesia
  • Heart arrhythmia
  • Post-herpetic neuralgia
πŸ‡ΊπŸ‡Έ
Approved in United States as Lidocaine for:
  • Local anesthesia
  • Regional anesthesia
  • Heart arrhythmia
  • Post-herpetic neuralgia
  • Skin graft donor site pain
πŸ‡¨πŸ‡¦
Approved in Canada as Xylocaine for:
  • Local anesthesia
  • Regional anesthesia
  • Heart arrhythmia
πŸ‡―πŸ‡΅
Approved in Japan as Lidocaine for:
  • Local anesthesia
  • Regional anesthesia

Find a Clinic Near You

Who Is Running the Clinical Trial?

University of Illinois at Chicago

Lead Sponsor

Trials
653
Recruited
1,574,000+

Findings from Research

In a double-blind, cross-over study involving 10 cancer patients with cutaneous allodynia, intravenous lidocaine provided complete pain relief for one patient and partial relief for another, but overall, it did not significantly reduce pain intensity compared to placebo.
The study concluded that intravenous lidocaine is not recommended as a routine treatment for pain in cancer patients with cutaneous allodynia, highlighting the need for further research on its effects with different types of pain stimuli.
Trial of intravenous lidocaine on painful neuropathy in cancer patients.Ellemann, K., SjΓΆgren, P., Banning, AM., et al.[2019]
Lidocaine hydrochloride 3.5% ophthalmic gel achieves maximum concentration in ocular tissues within 20 minutes of application, indicating rapid onset of action for topical ocular anesthesia.
The gel demonstrates high intraocular penetration with significantly lower systemic exposure, making it an effective and safe local anesthetic for ophthalmic procedures, with longer elimination half-lives in ocular tissues compared to plasma.
Ocular and systemic pharmacokinetics of lidocaine hydrochloride ophthalmic gel in rabbits after topical ocular administration.Liu, B., Ding, L., Xu, X., et al.[2022]
In a survey of 437 dermatologic surgeons, the average volume of 1% lidocaine used for facial skin cancer excision was 3.44 mL, and for reconstruction, it was 11.70 mL, indicating that the amounts used are modest and within safe limits.
No cases of lidocaine toxicity were reported, and the incidence of mild adverse events related to anesthesia was very low (greater than 0.15%), suggesting that lidocaine is a safe option for local anesthesia in dermatologic procedures compared to general anesthesia.
Safety of Local Intracutaneous Lidocaine Anesthesia Used by Dermatologic Surgeons for Skin Cancer Excision and Postcancer Reconstruction: Quantification of Standard Injection Volumes and Adverse Event Rates.Alam, M., Schaeffer, MR., Geisler, A., et al.[2022]

References

Trial of intravenous lidocaine on painful neuropathy in cancer patients. [2019]
Ocular and systemic pharmacokinetics of lidocaine hydrochloride ophthalmic gel in rabbits after topical ocular administration. [2022]
Safety of Local Intracutaneous Lidocaine Anesthesia Used by Dermatologic Surgeons for Skin Cancer Excision and Postcancer Reconstruction: Quantification of Standard Injection Volumes and Adverse Event Rates. [2022]
Assessing the Pain Reaction of Children and Evaluation of Efficacy of Buccal Infiltration with Articaine and Inferior Alveolar Nerve Block with Lignocaine for Pulp Therapy in Primary Mandibular Second Molars. [2022]
Association between intraoperative intravenous lidocaine infusion and survival in patients undergoing pancreatectomy for pancreatic cancer: a retrospective study. [2020]
Safety and Efficacy of a Needle-free Powder Lidocaine Delivery System in Pediatric Patients Undergoing Venipuncture or Peripheral Venous Cannulation: Randomized Double-blind COMFORT-004 Trial. [2018]
Lidocaine overdose: another preventable case? [2019]
Lidocaine toxicity during frequent viscous lidocaine use for painful tongue ulcer. [2019]
Safety, efficacy, and patient acceptability of lidocaine hydrochloride ophthalmic gel as a topical ocular anesthetic for use in ophthalmic procedures. [2021]
10.United Statespubmed.ncbi.nlm.nih.gov
Continuous Lidocaine Infusions to Manage Opioid-Refractory Pain in a Series of Cancer Patients in a Pediatric Hospital. [2017]
Intraarterial Lidocaine Administration for Pain Control by Water-in-Oil Technique in Transarterial Chemoembolization: in vivo and Randomized Clinical Trial. [2022]
Efficacy of intra-arterial lidocaine infusion in the treatment of cerulein-induced acute pancreatitis. [2020]
Intraoperative lidocaine infusion in patients undergoing pancreatectomy for pancreatic cancer: a mechanistic, multicentre randomised clinical trial. [2023]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of ServiceΒ·Privacy PolicyΒ·CookiesΒ·Security